Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy
Figure 5
Hematoxylin and eosin (H&E) and IgG stained representative heart sections.
Cardiac damage in 20 week-old mdx mice is very mild and slightly attenuated by LS treatment. However, P treatment augments the damage present in mdx hearts as observed by both IgG stained myocytes as well as regions where cardiac muscle has been replaced by fibrotic scars as observed in H&E stained sections. C: C57BL/10; U: untreated mdx mice, P: Prednisolone treated mdx mice, LS: Lisinopril-Spironolactone treated mdx mice; LSP, Lisinopril-Spironolactone-Prednisolone treated mdx mice; TS: Losartan-Spironolactone treated mdx mice; TSP: Losartan-Spironolactone-Prednisolone treated mdx mice. Bar = 100 µm.